Background: Ankylosing spondylitis (AS) is inflammation of the sacroiliac joints and ‎spine, associated with clinical symptoms such as pain and stiffness in ‎the vertebral column, after which, in a considerable number of ‎individuals, new bone growth occurs. Objective: The current research study attempted to find out whether the ‎presence of SNPs in TNF receptor [TNFRSF1A ‎‎(rs767455), TNFRSF1B‎‎ (rs1061622)] encoding genes could influence ‎patients' outcomes to etanercept in a specimen of Iraqi AS patients. Patients and methods: ‎Sixty patients with established AS receiving only etanercept were ‎selected to be enrolled in this research with a ‎mean age of 40.75 ± 8.67 ‎years, 51 patients of them were males and only 9 patients were females. ‎Patients were ‎classed as "responders" if just obtained a BASDAI 50 ‎clinical response and as "non-responders" if they can't ‎achieve a ‎BASDAI 50 clinical elaboration after at least 6 months treatment. ‎After PCR products amplification ‎of purified blood DNA, TNF ‎receptor (TNFRSF1A and TNFRSF1B‎‎) genes SNPs were established ‎by Sanger ‎sequencing. Results: The analysis of this study expressed that there was a significant ‎incidence of TT genotype of rs1061622 (P = 0.022) in responder ‎group, whereas the TG genotype of the same SNP was considerably ‎present in the group that did not respond (P = 0.002). Finally, a ‎non-significant difference existed in alleles and genotypes frequency ‎between responder and non-responder groups of rs767455 SNP ‎in TNFRSF1A gene. Conclusions: The wild TT genotype of rs1061622 predicts etanercept ‎responsiveness in ankylosing spondylitis patients. The TG genotype ‎of the same SNP increases the probability of non-responding.